MATTERHORN: perioperative durvalumab plus FLOT improves overall survival

The Lancet,

0.78

Hazard ratio for death

95% CI 0.63–0.96; p=0.021

Patients, randomized
948
Double-blind, placebo-controlled
Phase 3

Take-home

The phase 3 MATTERHORN trial found that adding perioperative durvalumab to FLOT chemotherapy significantly improved overall survival in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.

Among 948 randomized patients, durvalumab reduced the risk of death by 22% compared with placebo (HR 0.78; 95% CI 0.63–0.96; p=0.021).

These results support perioperative durvalumab plus FLOT as a new standard treatment option, with no major unexpected safety signal

Read the paper in The Lancet

Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

More on gastrointestinal cancers